Floatz logo

Axicabtagene Ciloleucel

B-cell Lymphoma Recurrent

Lyell Immunopharma, Inc.Cell therapyPhase 4 / ApprovedActive
BBB
76/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
63/ 100
Competitive Position
95/ 100

Competitive context

8 Active assets in the B-cell Lymphoma Recurrent cohort.

Asset / SponsorPhaseRating
yy-20394
Jiangsu HengRui Medicine Co., Ltd.
Phase 2B
Recombinant Humanized Monoclonal Antibody Mil62
Beijing InnoCare Pharma Tech Co., Ltd.
Phase 1/2CCC
Abiraterone Acetate
Universität Münster
Phase 2CCC
Enzalutamide
Universität Münster
Phase 2CCC
Docetaxel
Universität Münster
Phase 2CCC

View all 9 →

Same molecule, other indications

Axicabtagene Ciloleucel is also rated in:

Recurrent Transformed Follicular Lymphoma to Diffuse Large B-Cell LymphomaDormant
BBB
Indicative ·
77 / 100
View asset →
diffuse large B-cell lymphomaDormant
BBB
Indicative ·
75 / 100
View asset →
primary mediastinal large B-cell lymphomaDormant
BB
Indicative ·
71 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →